Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1786 to 1800 of 8975 results

  1. Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 [TSID11807]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Macitentant–tadalafil for treating pulmonary arterial hypertension [TSID10517]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Aflibercept for untreated diabetic macular oedema [TSID10621]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation